The precise role of regulatory T cells in cancer outcomes warrants further consideration given that several groups are attempting to enhance tumor immunity by depleting FoxP3+ Tregs from cancer patients [39]-[44], including EOC patients [45]. The gene discussed is FOXP3; the disease is neoplasm.